Recruiting

Digital Cognitive Tests

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT07710131

Conditions

PCNSL

Brain Tumor

Cognitive Dysfunction

IDH Mutation

Low-grade Glioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)

Traditional Neuropsychological Testing

Quality of Life and Mood Questionnaires

Brain MRI (Standard of Care)

Study Details

Brief summary:

This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.

Conditions

PCNSL

Brain Tumor

Cognitive Dysfunction

IDH Mutation

Low-grade Glioma

Study ID

NCT07710131

Start date

Sep 2, 2026

Status verified date

Nov, 2026

Completion date

Jan 1, 2029

Anticipated

Primary completion date

Jan 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR
  • Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable).
  • Age ≥ 18 years.
  • Ability to consent to study.

Exclusion Criteria:

  • Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print.
  • Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.

Study Design

Enrollment

36 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: Digital Cognitive Assessment

Participants with newly diagnosed PCNSL or IDH-mutant LGG will undergo both traditional neuropsychological testing and digital cognitive assessments (TestMyBrain and Mobile Toolbox) at specified timepoints (baseline, 6 months, post-treatment or 12-14 months). Quality of life and mood questionnaires will also be administered. Brain MRI data will be collected as part of standard care. Participants will be sent a link to complete the digital cognitive tests at home. Questionnaires will also be sent via email to complete. Data will be collected from brain MRIs obtained as part of standard of care/routine surveillance.

  • Screening visit
  • Baseline visit (2- months)
  • Follow-Up visit (3-month)
  • End of Treatment 2 months after completing treatment (PCNSL only)
  • Final Assessment 12-14 months after baseline (LGG only).
  • Brain MRI (standard of care) based on participant permission

There is no follow-up care as part of this research study.

Interventions

Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)

Participants will complete a battery of digital cognitive tests using the TestMyBrain and Mobile Toolbox platforms, assessing attention, processing speed, executive function, and memory. Assessments will be conducted in clinic and at home at multiple timepoints.

Traditional Neuropsychological Testing

Participants will complete standard paper-and-pencil neuropsychological tests, including WAIS-IV Digit Span, Brief Test of Attention, Symbol Digits Modalities Test, Trail Making Test Parts A and B, Stroop, and Hopkins Verbal Learning Test-Revised.

Quality of Life and Mood Questionnaires

Participants will complete the Functional Assessment of Cancer Therapy - Brain (FACT-br) and Hospital Anxiety and Depression Scale (HADS) at baseline and follow-up timepoints.

Brain MRI (Standard of Care)

Brain MRI data will be collected as part of routine clinical care to assess tumor response, stability, or progression, and correlated with cognitive test results.

Primary outcome measure

  • Evaluating the Construct Validity of Digital Cognitive Tests [ Time Frame: Baseline assessment only, conducted at study enrollment for each participant. ]
  • Evaluating the Discriminant Validity of Digital Cognitive Tests with Emotional Wellbeing Measures [ Time Frame: Baseline ]
  • Assessing Test-Retest Reliability of the Digital Cognitive Tests Across Repeated Administrations and Different Environments. [ Time Frame: Baseline, 6 and 12 month follow ups ]

Central Contacts and Locations

Central contacts

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • Primary Central Nervous System Lymphoma (PCNSL)
  • IDH-Mutant Low-Grade Glioma (LGG)
  • Brain Tumors
  • Cognitive Dysfunction

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.